About Kelonia Therapeutics
Kelonia Therapeutics develops advanced technologies for delivering genetic material to specific tissues, aiming to treat diseases at their source. Their flagship product, KLN 1010, is an in vivo CAR T cell therapy designed for multiple myeloma, which modifies a patient's immune cells to target cancer cells directly within the body. This approach simplifies treatment and enhances accessibility. Unlike many competitors, Kelonia emphasizes a patient-first mission and fosters a human-first culture to attract talent. Their goal is to provide life-saving genetic therapies through strategic partnerships and innovative solutions.
Boston, MassachusettsHeadquarters
2021Year Founded
$48.6MTotal Funding
SERIES_ACompany Stage
Biotechnology, HealthcareIndustries
51-200Employees
Risks
Competition in in vivo CAR-T therapies could impact market share.
FDA scrutiny may delay clinical trials and approvals for Kelonia's products.
Reliance on partnerships exposes Kelonia to risks if collaborations face challenges.
Differentiation
Kelonia's iGPS technology offers precise, efficient in vivo gene delivery.
KLN 1010 is the first in vivo CAR T cell therapy for multiple myeloma.
Kelonia's patient-first mission emphasizes accessible, life-saving genetic medicines.
Upsides
Kelonia's partnership with Astellas could accelerate innovation and market entry.
iGPS technology aligns with demand for less invasive therapeutic options.
Industry leaders on Kelonia's board strengthen its strategic and regulatory navigation.
Funding
Total raised$48.64 M
Latest valuation$250.00 M
StageSERIES_A
SERIES A
3/31/2022$50
$250.00 M